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The drug tamoxifen is widely used in the chemotherapy of breast cancer but its action is not explained com- 
pletely by its anti-oestrogen properties. We now present evidence indicating that it is also a potent inhibitor 
of eukaryotic protein synthesis as demonstrated in Xenopur oocytes, intact reticulocytes and reticulocyte 
lysates. The inhibition affects general protein synthesis, is transient in oocytes and not reversed by oestrogen. 
The drug appears to act by inhibiting polypeptide chain elongation. This action of tamoxifen is independent 
of oestrogen receptors and may explain its therapeutic effectiveness in oestrogen-independent tumours. 
Tamoxtyen Anti-estrogen Protein synthesis Polypeptide elongation Breast cancer 
1. INTRODUCTION 
The non-steroidal anti-oestrogen drug tamox- 
ifen (Nolvadex)* has been used to treat breast 
cancer for over a decade. Recently, two extensive 
reviews [ 1,2] have examined the hypothesis that the 
anti-tumour activity is due to binding of tamoxifen 
to the oestrogen receptor of cells thereby blocking 
the response to the hormone. Both articles con- 
clude that there is evidence, for instance the inhibi- 
tion of an oestrogen receptor-negative cell line [3], 
suggesting the existence of another mechanism of 
action of tamoxifen in addition to its anti- 
oestrogen activity. 
Whilst using tamoxifen as an anti-oestrogen in 
Xenopus oocytes we made the fortuitous observa- 
tion that the drug inhibits the incorporation of 
[35S]methionine into trichloroacetic acid-pre- 
cipitable material. Since active messenger RNA 
could be isolated from oocytes after treatment with 
tamoxifen it seemed likely that the observed effect 
* Tamoxifen is (Z)-2-[4-(1,2-diphenylbut-l-enyl)pheno- 
xy]-iV,N-dimethylethanamide, which is produced by 
Imperial Chemical Industries under the tradename 
Nolvadex 
was due to inhibition of RNA translation. In this 
paper we report that protein synthesis is inhibited 
by tamoxifen in intact oocytes and reticulocytes, as 
well as in reticulocyte lysates, at concentrations 
which are similar to those obtained in vivo with 
therapeutic doses of the drug. The inhibition is 
rapid in all systems and appears to involve a block 
at elongation as shown by the absence of 
polyribosome disaggregation in the presence of the 
drug. Also, since inhibition is observed in systems 
lacking the oestrogen receptor it seems to be in- 
dependent of the anti-oestrogen activity of 
tamoxifen. 
2. MATERIALS AND METHODS 
2.1. Preparation and use of reticulocyte lysates 
Reticulocytes were obtained from the blood of 
New Zealand white rabbits made anaemic by sub- 
cutaneous injections of neutralized phenyl- 
hydrazine and lysates were prepared as described 
[4]. Incubation mixtures for measuring cell-free 
protein synthesis by the incorporation of 
[%]methionine into trichloroacetic acid-pre- 
cipitable radioactivity were set up and used as in 
[4]. Where indicated tamoxifen in ethanol was 
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added, giving appropriate amounts of the drug and 
a final concentration of ethanol of 1%. Radioac- 
tivity was measured in an LKB minibeta scintilla- 
tion spectrometer. 
2.2. Preparation and culture of rabbit 
reticulocytes 
Washed reticulocytes were prepared as for lysis 
[4] and cultured at lo8 cells/ml in NCTC-135 
growth medium supplemented with 10% foetal 
calf and 2% rabbit serum (Gibco-Biocult), ferrous 
ammonium sulphate (lOpM), glutamine (2 mM) 
and containing 100 U/ml of a penicillin- 
streptomycin solution. Preincubation of a cell 
suspension (20 ml) was carried out in an 80 cm3 
Nunclon bottle (Gibco-Biocult) in a humidified in- 
cubator at 365°C in an atmosphere containing 5% 
COz. After 4 h, aliquots of the suspension (2 ml) 
were similarly incubated in 25 cm3 Nunclon bottles 
after treatment as described in the figure legends. 
Cells were harvested by centrifugation, washed 
with 130 mM NaCl, 5 mM KCl, 7.5 mM MgC12 
(2 x 10 ml) and lysed with water (150 ~1). Aliquots 
of the lysate (5 ~1) were assayed for trichloroacetic 
acid-precipitable radioactivity as above. 
2.3. Preparation and culture of Xenopus oocytes 
An ovary lobe was removed from a female 
Xenopus laevis, large healthy oocytes were selected 
after mechanical stripping and incubated at 21°C 
overnight in MBS medium [5]. Groups of 5 oocytes 
were then incubated under the stated conditions in 
fresh MBS medium (50~1) in Nunclon 96-well 
microtitre plates. Extraction of oocyte proteins 
was carried out according to Colman [5] and 
trichloroacetic acid-precipitable radioactivity 
assayed as above. Proteins were analysed by SDS- 
PAGE [6] and revealed by fluorography [7]. 
2.4. Analysis of polyribosomes 
After incubation of reticulocyte lysates (0.2 ml) 
for 12 min at 30°C under optimal protein syn- 
thesizing conditions, 1 vol. cold RS buffer (10 mM 
Tris-Cl, pH 7.6, 10 mM KCl, 1.5 mm MgC12) con- 
taining lOtg/ml cycloheximide was added. The 
mixtures were then loaded immediately onto 
15-30010 isokinetic sucrose gradients prepared in 
RS buffer and centrifuged in a Beckman SW40 
rotor at 185000 x gav for 2 h at 4°C. Gradients 
were fractioned by upward displacement hrough 
122 
an ISCO fractionator and analysed by monitoring 
the absorbance at 254 nm. 
2.5. Materials 
[35S]Methionine (1120 Ci/mmol) was purchased 
from New England Nuclear Corporation. Tamox- 
ifen was a gift from Dr B. Furr (ICI Phar- 
maceuticals). A stock solution in absolute ethanol 
was prepared daily. Cycloheximide and 17,& 
oestradiol were from Sigma and all other chemicals 
were of Analar grade as supplied by BDH. 
3. RESULTS 
3.1. Inhibition of protein synthesis by tamoxifen 
The effect of different tamoxifen concentrations 
on cell-free protein synthesis in reticulocyte lysate 
is shown in figs 1 and 2. The inhibition observed 
was rapid. At tamoxifen concentrations of 18 pM 
and 180 nM, which include those found in 
tumours and other tissues, protein synthesis was 
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Fig.1. Inhibition of protein synthesis by tamoxifen. An 
untreated reticulocyte lysate was incubated under 
conditions of optimal protein synthesis with 
[35S]methionine (17 ,&i) at 30°C for up to 45 min with 
or without tamoxifen. Ethanol (1070) was included in the 
control. At the times shown aliquots (5 ~1) were removed 
and assayed for trichloroacetic acid-precipitable 
radioactivity. 
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Fig.2. The effect of various concentrations of tamoxifen 
upon protein synthesis in reticulocyte lysates. 
Reticulocyte lysate was incubated at 30°C with 
[“Slmethionine (17&i) in the presence of various 
amounts of tamoxifen or 1% ethanol (control). After 
30 min aliquots were removed from the solution and 
assayed for trichloroacetic acid-precipitable 
radioactivity. In the absence of tamoxifen the level of 
incorporation was 179385 counts/min. 
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Fig.3. Inhibition of protein synthesis by tamoxifen in 
intact reticulocytes. Reticulocytes (2 x lo9 cells) were 
preincubated in NCTC-135 medium (20 ml) for 4 h at 
35°C. The cell suspension was divided into 10 portions 
(2 ml), which were incubated with [3sS]methionine 
(17&i) with or without tamoxifen (7 PM). Ethanol 
(1 Vo) was included in the control flasks. At 1 h intervals 
cells were collected, washed with Borsook saline and 
lysed with water (HO&. Aliquots (S/cl) of the lysates 
were then assayed for trichloroacetic acid-precipitable 
radioactivity. 
decreased by more than 90% and 50%, respective- 
ly, after 3 min and a very low rate of protein syn- 
thesis continued throughout the 45 min. The range 
of concentrations over which tamoxifen inhibited 
protein synthesis extends at least as low as 180 nM, 
but at no concentration could synthesis be stopped 
completely. Treatment of lysates with tamoxifen 
and various concentrations of 17&oestradiol 
(10 nM-20/M), at the start of or during incuba- 
tion failed to reverse the inhibition. Inhibition also 
occurred in whole reticulocytes (fig.3). 
When Xenopus oocytes were incubated in the 
presence of 1.5 ,uM (fig.4) or 7 pM tamoxifen (not 
shown), 40-50% inhibition of protein synthesis 
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Fig.4. Tamoxifen inhibits protein synthesis in Xenopus 
oocytes. Oocytes were removed from a single female 
Xenopus. After mechanical separation groups of 5 were 
incubated at 21°C in MBS medium (50 ~1) containing 
either ethanol (1%) or 1.5 /cM tamoxifen in ethanol. At 
the times shown the oocytes were labelled for 2 h with 
[3SS]methionine (8.4 &i), then homogenised in buffer 
containing protease inhibitors (100 ~1) and the 
homogenate was centrifuged to pellet cell debris. 
Aliquots of the supernatant (5 $1) were assayed for 
trichloroacetic acid-precipitable radioactivity. 
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was observed in both cases in 4 h. This inhibition 
was then reversed after 16 h but t-e-established by 
a further addition of the drug. 
Qualitative analysis of the proteins made in 
oocytes during exposure to tamoxifen by SDS- 
PAGE showed no differences (not shown). 
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3.2. Pol~r~~o~orne bronzes during tamox~fe~ 
treatment 
Sucrose-gradient analyses of reticulocyte Iysates 
containing 0, 0.5 or 7 pM tamoxifen are shown in 
fig.5. Incubation times were chosen to allow 
ribosomes to run off the mRNA in controls. This 
B 
D 
Fig.5 Polyribosome profiles from tamoxifen-treated reticulocyte lysates. Reticulocyte lysates were incubated at 30°C 
with [3sS]methionine in two separate xperiments. Protein synthesis was stopped after 12 min by addition of I vol. RS 
buffer containing cycloheximide (10 pg/ml). The solutions were loaded imm~iately onto 1%30% isokinetic sucrose 
gradients, centrifuged at 185000 x g for 2 h and fractionated by upward displacement hrough an ISCO fractionator. 
(A) Control lysate (1% ethanol); (B) lysate incubated in the presence of tamoxifen (7 pM); (C) control lysate (1% 
124 
ethanol); (D) lysate incubated in the presence of tamoxifen (0.5 ,uM). 
Volume 207, number 1 FEBS LETTERS October 1986 
process was stopped by 7 ,uM tamoxifen which 
produced a pattern identical with that of an unin- 
cubated lysate (not shown). Run off was also slow- 
ed by 0.5 pM tamoxifen. 
Tamoxifen (7 /cM) produced no change in the 
binding of [35S]methionine to the 48 S preinitiation 
complex compared with controls (not shown). 
4. DISCUSSION 
In our experiments tamoxifen inhibited protein 
synthesis both in reticulocyte lysates and intact 
reticulocytes. Additionally it decreased protein 
synthesis in Xenopus oocytes, either by a direct ef- 
fect or as a result of a decrease in the synthesis of 
other macromolecules uch as mRNA. In all cases, 
the inhibition was rapid and observed at concen- 
trations found in tumours and other tissues during 
chemotherapy with this drug [2]. Oestradiol 
neither prevented nor reversed the inhibition and 
this, together with the fact that oocytes [8] and 
presumably reticulocytes have no oestrogen recep- 
tor, suggests that this effect is unrelated to the anti- 
oestrogen properties of the drug. 
No concentration of tamoxifen up to 18 /rM ap- 
peared to inhibit protein synthesis completely in 
reticulocyte lysates. This may be due to specific 
protein(s) being unaffected by the drug or to a 
general continuation of synthesis as observed with 
some other inhibitors [lo]. The latter explanation 
is favoured for 2 reasons. First, globin synthesis 
accounts for 90%. of protein synthesis in 
reticulocytes and no other component would be 
able to account for the 30% of residual synthesis 
in the presence of tamoxifen. Secondly, analysis of 
proteins made by oocytes indicated that tamoxifen 
does not alter significantly the proportions in 
which different proteins are synthesized. 
Analysis of the size classes of polysomes present 
in control and tamdxifen-treated reticulocyte 
lysates, together with the fact that there was no 
decrease in the binding of [35S]methionine to the 
48 S preinitiation complex, suggests that the drug 
acts on the elongation step in protein synthesis 
rather than on initiation. 
The recovery of protein synthesis in oocytes 
treated with tamoxifen after 16 h suggests that this 
cell may metabolize or sequester the drug within a 
considerably shorter time than the 7 day half-life 
reported for whole animals. 
The inhibition of protein synthesis in 
reticulocyte lysates, reticulocytes and Xenopus 
oocytes evidently does not require the presence of 
the oestrogen receptor. In reticulocyte lysates the 
drug acts upon elongation and the effect is not 
reversible by oestrogen. This general effect of pro- 
tein synthesis may be similar to that reported by 
Stewart and Stern [9], who showed that 1OOyM 
tamoxifen slows protein synthesis in foetal rat 
bone. Despite the different cell types, inhibition of 
protein synthesis may provide a possible explana- 
tion for the action of tamoxifen as an anti-tumour 
agent against oestrogen receptor-negative cells. 
Should tamoxifen inhibit protein synthesis in 
breast cancer cells in a manner similar to that 
observed here, the differences in drug concentra- 
tions between tumour and non-tumour tissues 
discussed in recent reviews [1,2] may account for 
its selective anti-tumour action. At a concentration 
of 6.7 pM, which is found in tumours, tamoxifen 
would cause a 70% reduction in protein synthesis 
slowing growth markedly or causing cell death. In 
contrast, the 0.53 PM concentrations found in 
other tissues would reduce protein synthesis by on- 
ly 20%, which is likely to have a much less pro- 
found effect. 
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